Frdric Charlotte

List of Publications by Citations

53 papers	3,097 citations	24 h-index	55 g-index
57 ext. papers	3,863 ext. citations	3.9 avg, IF	4.53 L-index

#	Paper	IF	Citations
53	Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. *Blood*, **2016**, 127, 2672-81	2.2	675
52	High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. *Blood*, **2012**, 120, 2700-3	2.2	469
51	Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. *Journal of Clinical Oncology*, **2015**, 33, 411-8	2.2	186
50	Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. *Blood*, **2018**, 131, 2877-2890	2.2	185
49	Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. *Blood*, **2014**, 124, 1119-26	2.2	163
48	Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. *Blood*, **2014**, 124, 3016-9	2.2	157
47	Histiocytoses: emerging neoplasia behind inflammation. *Lancet Oncology, The*, **2017**, 18, e113-e125	21.7	124
46	Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. *Blood*, **2011**, 117, 2783-90	2.2	113
45	Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). *Blood*, **2017**, 130, 1377-1380	2.2	95
44	Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells. *Blood*, **2016**, 128, 1651-9	2.2	73
43	High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. *Blood*, **2017**, 130, 1007-1013	2.2	69
42	Treatment of Erdheim-Chester disease with long-term high-dose interferon- *Seminars in Arthritis and Rheumatism*, **2012**, 41, 907-13	5.3	63
41	Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. *BMJ Open Gastroenterology*, **2016**, 3, e000075	3.9	62
40	Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. *Blood*, **2017**, 130, 176-180	2.2	60
39	Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort. *American Journal of Hematology*, **2018**, 93, E114-E117	7.1	53
38	Cutaneous manifestations of Erdheim-Chester disease (ECD): Clinical, pathological, and molecular features in a monocentric series of 40 patients. *Journal of the American Academy of Dermatology*, **2016**, 74, 513-20	4.5	52
37	Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. *Blood*, **2016**, 127, 1509-12	2.2	44

36	The FAT Score, a Fibrosis Score of Adipose Tissue: Predicting Weight-Loss Outcome After Gastric Bypass. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 2443-2453	5.6	37
35	Ectopic Germinal Center-Like Structures in Minor Salivary Gland Biopsy Tissue Predict Lymphoma Occurrence in Patients With Primary Sjögren's Syndrome. *Arthritis and Rheumatology*, **2018**, 70, 1481-1488	9.5	34
34	Erdheim-Chester disease in childhood: a challenging diagnosis and treatment. *Journal of Pediatric Hematology/Oncology*, **2009**, 31, 782-6	1.2	34
33	Ocular adnexal marginal zone B cell lymphoma: a clinical and pathologic study of 23 cases. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2006**, 448, 506-16	5.1	33
32	The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm. *Expert Review of Clinical Immunology*, **2015**, 11, 1033-42	5.1	30
31	Simple, Reproducible, and Efficient Clinical Grading System for Murine Models of Acute Graft-versus-Host Disease. *Frontiers in Immunology*, **2018**, 9, 10	8.4	28
30	Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. *Journal of Hepatology*, **2020**, 72, 828-838	13.4	22
29	Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding. *Journal of Hepatology*, **2015**, 62, 816-21	13.4	21
28	Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by. *Haematologica*, **2020**, 105, e5-e8	6.6	20
27	Efficacy of infliximab in the treatment of Erdheim-Chester disease. *Annals of the Rheumatic Diseases*, **2018**, 77, 1387-1390	2.4	18
26	Do We Really Need to Wear Proper Eye Protection When Using Holmium:YAG Laser During Endourologic Procedures? Results from an Ex Vivo Animal Model on Pig Eyes. *Journal of Endourology*, **2016**, 30, 332-7	2.7	18
25	SASH1, a new potential link between smoking and atherosclerosis. *Atherosclerosis*, **2015**, 242, 571-9	3.1	17
24	Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 1117-1127	6.1	14
23	Highly sensitive methods are required to detect mutations in histiocytoses. *Haematologica*, **2019**, 104, e97-e99	6.6	13
22	Erdheim-Chester disease: a rapidly evolving disease model. *Leukemia*, **2020**, 34, 2840-2857	10.7	10
21	Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors. *Haematologica*, **2019**, 104, e502-e505	6.6	9
20	The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. *European Journal of Gastroenterology and Hepatology*, **2019**, 31, 393-402	2.2	8
19	LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. *Alimentary Pharmacology and Therapeutics*, **2019**, 49, 308-320	6.1	8

18	High frequency of clonal hematopoiesis in Erdheim-Chester disease. *Blood*, **2021**, 137, 485-492	2.2	8
17	Transient antibody targeting of CD45RC inhibits the development of graft-versus-host disease. *Blood Advances*, **2020**, 4, 2501-2515	7.8	6
16	Highly selective inhibitor of inducible nitric oxide synthase enhances S-antigen-induced uveitis. *Current Eye Research*, **2003**, 26, 1-7	2.9	6
15	Bifunctional Therapeutic Peptides for Targeting Malignant B Cells and Hepatocytes: Proof of Concept in Chronic Lymphocytic Leukemia. *Advanced Therapeutics*, **2020**, 3, 2000131	4.9	6
14	Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. *European Journal of Gastroenterology and Hepatology*, **2020**, 32, 998-1007	2.2	5
13	Acute mast cell leukemia: A rare but highly aggressive hematopoietic neoplasm. *Diagnostic Cytopathology*, **2018**, 46, 639-641	1.4	3
12	Bi-Functional Peptides as a New Therapeutic Tool for Hepatocellular Carcinoma. *Pharmaceutics*, **2021**, 13,	6.4	3
11	Temporal arteritis in IgG4 related disease. *Joint Bone Spine*, **2021**, 88, 105087	2.9	3
10	Angioimmunoblastic T-Cell Lymphoma (AITL) Is the Most Prevalent T-Cell Lymphoma Entity in Western Europe. *Blood*, **2012**, 120, 1607-1607	2.2	2
9	Perirenal fibrosis: make your diagnosis. *CKJ: Clinical Kidney Journal*, **2013**, 6, 543-4	4.5	1
8	Auto-Immune Origin of B Cells from HCV-Associated Lymphoma. *Blood*, **2015**, 126, 1464-1464	2.2	1
7	Reply. *Arthritis and Rheumatology*, **2019**, 71, 171-172	9.5	1
6	Quantitative and Qualitative Approach for Shear Wave Elastography in Superficial Lymph Nodes. *Ultrasound in Medicine and Biology*, **2021**, 47, 2117-2127	3.5	1
5	Blood Flow Cytometry Allows Us To Dispense with Bone Marrow Biopsy in the Evaluation of Treatment Response in CLL.. *Blood*, **2004**, 104, 4769-4769	2.2	
4	PD-1/ PD-L1 Expression Is Associated with Tissue Inflammation and BRAF Status in Erdheim-Chester Disease. *Blood*, **2018**, 132, 4380-4380	2.2	
3	Langerhans cell histiocytosis in children: Correlation of BRAF status with clinical characteristic.. *Journal of Clinical Oncology*, **2015**, 33, 10003-10003	2.2	
2	Treatment of Erdheim-Chester disease patients with the MEK inhibitor cobimetinib.. *Journal of Clinical Oncology*, **2016**, 34, e19074-e19074	2.2	
1	Association of Langerhans Cell Histiocytosis with Erdheim-Chester Disease: How Close Monocyte/Macrophage and Dendritic Cell Lineages Are?. *Blood*, **2010**, 116, 4716-4716	2.2	